Interview – Proactive Investors
Daryl Rebeck featured on Proactive Investors with Steve Darling at the LD Micro event on September 4, 2018.
Pinnacle Digest Podcast
Pinnacle Digest recently featured LexaGene in a podcast showcasing LexeGene’s new state-of-the-art labs and speaking with CEO Jack Regan.
LexaGene on Capital Ideas TV
Capital Ideas TV recently featured LexaGene CEO Jack Regan to discuss plans for commercialization of the LX6 system.
Pandemic byline in Hospital & Healthcare
What would happen in the event of a deadly new strain of influenza? Dr. Jack Regan discusses the importance of open-access diagnostics in pandemic prevention. Read his byline in Hospital & Healthcare Management.
LexaGene was featured recently in Cleanroom Technology where we spoke about LexaGene’s mission to make it as simple and easy as possible for people to detect pathogens.
Medgadget talks to CEO Dr. Jack Regan about LexaGene’s LX6 Rapid Pathogen Detection System.
Ellis Martin Report with Daryl Rebeck – March 2018
Listen to LexaGene President Daryl Rebeck’s interview with Troy Duran for the Ellis Martin Report.
Food Quality and Safety byline
Much needed innovation in food safety testing is within sight . . . Read Dr. Jack Regan’s byline in Food Quality and Safety.
Food Quality News
CEO Jack Regan discusses LexaGene’s approach to food safety and plans over the next 6-10 months in Food Quality News.
LexaGene in Food Engineering News
Food industry news magazine Food Engineering featured LexaGene in a recent article, interviewing Dr. Jack Regan about LexaGene’s rapid-testing technology.
USA Weekly profile
Dr. Jack Regan discusses LexaGene, his passion for the company, the biggest business challenge, and what advice he would give his younger self in this profile in USA Weekly.
Ellis Martin Report with Daryl Rebeck – November 2018
In this interview for The Ellis Martin Report, co-host Troy Duran chats with LexaGene’s President Daryl Rebeck about the company’s breakthrough microfluidic technology. Mr. Rebeck explains why he believes there is recent interest in the Lexagene story. Listen to the report.